Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Pasireotide
Drug ID BADD_D01684
Description Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease.
Indications and Usage For the treatment of Cushing’s disease, specifically for those patients whom pituitary surgery has not been curative or is not an option.
Marketing Status approved
ATC Code H01CB05
DrugBank ID DB06663
KEGG ID D10147
MeSH ID C517782
PubChem ID 9941444
TTD Drug ID D0TV0C
NDC Product Code 71161-128; 71161-129; 55292-133; 55292-142; 55292-143; 55292-139; 55292-141; 71161-130; 71161-127; 71161-126; 55292-140; 55292-131; 55292-132
UNII 98H1T17066
Synonyms pasireotide | cyclo((4R)-4-(2-aminoethylcarbamoyloxy)-L-prolyl-L-phenylglycyl-d-tryptophyl-L-lysyl-4-o-benzyl-L-tyrosyl-L-phenylalanyl-) | SOM-230 | SOM 230 | SOM230
Chemical Information
Molecular Formula C58H66N10O9
CAS Registry Number 396091-73-9
SMILES C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4 )OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Presyncope02.11.04.013; 24.06.02.010; 17.02.05.0090.000186%
Prothrombin level increased13.01.02.011--Not Available
Pruritus23.03.12.001--
Pyrexia08.05.02.0030.000279%
Renal failure20.01.03.0050.000279%Not Available
Sinus bradycardia02.03.03.009--
Somnolence19.02.05.003; 17.02.04.0060.000279%
Syncope02.11.04.015; 24.06.02.012; 17.02.04.0080.000186%
Tachycardia02.03.02.0070.000186%Not Available
Therapeutic response decreased08.06.01.0160.000596%Not Available
Therapeutic response unexpected08.06.01.0010.000410%Not Available
Vertigo17.02.12.002; 04.04.01.003--
Vision blurred17.17.01.010; 06.02.06.0070.000373%
Vitamin D deficiency14.12.03.0030.000186%Not Available
Vomiting07.01.07.0030.002198%
General physical health deterioration08.01.03.0180.000279%Not Available
Malignant neoplasm progression16.16.01.0050.000466%Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Haemorrhage24.07.01.002--Not Available
Decreased appetite14.03.01.005; 08.01.09.0280.000969%
Pituitary tumour benign16.37.02.001; 05.03.05.0030.000186%Not Available
Drug intolerance08.06.01.0130.000596%Not Available
Type 2 diabetes mellitus14.06.01.003; 05.06.01.0030.000745%Not Available
Concomitant disease progression08.01.03.0640.000186%Not Available
Glucocorticoid deficiency05.01.02.011; 14.11.01.0370.000373%Not Available
Hyperglycaemic hyperosmolar nonketotic syndrome17.02.04.022; 14.07.04.009; 05.07.04.0090.000186%Not Available
The 4th Page    First    Pre   4    Total 4 Pages